David Miller, MD
Internal Medicine · Saugus, MANPI 1275547622
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,760 of the $2,969 with a category attached, or 93.0%. EMD Serono, Inc. accounts for 93.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,205 and has fallen 67.0% since, to $726 in 2021. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $247.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$3K
- AstraZeneca$107
- CSL Behring$89
- Genentech USA, Inc.$13
Across 1 payment — averaging $66,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$66K
What the payments were for
- Consulting fees$2,76093%
- Food & beverage$2097%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 2 | $2,760 |
| AstraZeneca | 5 | $107 |
| CSL Behring | 4 | $89 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,969 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $158,534 |
| OzempicSemaglutide | 55 | $73,793 |
| JardianceEmpagliflozin | 32 | $46,936 |
| XareltoRivaroxaban | 17 | $27,911 |
| WegovySemaglutide | 16 | $21,566 |
| EntrestoSacubitril/Valsartan | 18 | $11,111 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,179 |
| MyrbetriqMirabegron | 15 | $8,757 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,588 |
| Atorvastatin Calcium | 364 | $5,192 |
| Omeprazole | 207 | $3,441 |
| Oxycodone Hcl | 110 | $3,363 |
| Metoprolol Succinate | 154 | $3,177 |
| Nadolol | 13 | $3,176 |
| Potassium Chloride | 30 | $2,468 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Saugus
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.